RxDoctor Payments DataLook up a doctor →

Ryan Hall, MD

Hematology & Oncology · Little Rock, ARNPI 1366761975

Payments from drug & device makers

$4,115,836in general payments, 2019–2025

Across 524 payments — averaging $7854.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene, Ltd.$2.9M
  • Beone Medicines Ltd.$433K
  • AstraZeneca$245K
  • Merck$219K
  • Pfizer$142K
  • Amgen$66K
  • plus $137K from 23 others
$139in research payments, 2019–2025

Across 1 payment — averaging $139.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$139

What the payments were for

  • Speaking & faculty fees$2,50054%
  • Travel & lodging$82718%
  • Food & beverage$69015%
  • Education$65014%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,115,836 in reported general payments places this provider in the 95th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$10,534,778
Medicare patients
1,431
Services billed
379,557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate114$1,802,253
PomalystPomalidomide32$763,635
CabometyxCabozantinib S-Malate28$724,028
KeytrudaPembrolizumab36$405,041
XtandiEnzalutamide26$346,009
VenclextaVenetoclax34$343,968
RevlimidLenalidomide21$333,037
IbrancePalbociclib21$325,088
ErleadaApalutamide23$322,696
Lenalidomide24$303,780
BrukinsaZanubrutinib17$264,718
Neulasta OnproPegfilgrastim34$209,428
VerzenioAbemaciclib13$201,746
ImfinziDurvalumab22$187,952
CalquenceAcalabrutinib Maleate12$185,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVenclexta, Lupron Depot$17$506,67767 claims
PfizerIbrance, Trazimera, Eliquis$141,596$494,970144 claims
Johnson & JohnsonErleada, Procrit, Xarelto$112$421,797119 claims
MerckKeytruda$219,030$405,04136 claims
AstraZenecaImfinzi, Calquence$245,331$373,30034 claims
Astellas Pharma US IncXtandi$299$346,00926 claims
Lilly USA, LLCVerzenio$123$201,74613 claims
AmgenXgeva$65,529$137,38043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 hematology & oncology providers in Arkansas.

Other hematology & oncology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →